and magnesium stearate.
Sponsors
Sling Therapeutics Inc.
Conditions
Disease (TED)Thyroid Eye Disease
Phase 2
A Multicenter, Extension Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Two Doses of Linsitinib in Subjects with Active, Moderate to Severe Thyroid Eye Disease (TED)
CompletedCTIS2022-502812-35-00
Start: 2023-10-26End: 2025-06-06Target: 6Updated: 2025-07-25
A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the
Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects with Active, Moderate to Severe Thyroid Eye Disease (TED)
CompletedCTIS2024-514449-12-00
Start: 2022-11-04End: 2025-09-26Target: 18Updated: 2025-10-27